Johnson & Johnson
Recent News About Johnson & Johnson
-
J&J to face pelvic mesh lawsuit in Philadelphia, under Pa. laws
PHILADELPHIA – Four of 15 claims in a lawsuit against Johnson & Johnson over its pelvic mesh product will proceed. -
Superior Court affirms win for J&J over Pa. woman's pelvic mesh implant injuries
HARRISBURG – The Superior Court of Pennsylvania ruled Tuesday that testimony from a plaintiff’s physician did not cause a Philadelphia jury to wrongly find in favor of a Johnson & Johnson subsidiary, in a pelvic mesh personal injury case decided last year. -
Should Indiana woman be allowed to use Pennsylvania courts to sue New Jersey company? Supreme Court to decide
HARRISBURG – The future of both pelvic mesh lawsuits and the concept of personal jurisdiction in the Commonwealth of Pennsylvania have the potential to be greatly impacted by arguments and a forthcoming decision in the Hammons v. Ethicon case, set to be argued before the state Supreme Court next week on March 10. -
Defendant improperly attached to J&J pelvic mesh lawsuit for plaintiff's benefit, judge rules
PHILADELPHIA – A federal court has decided that a woman suing Ethicon over allegations of a defective pelvic mesh device had improperly joined an extra defendant to the case and denied her motion to remand the case back to a state court. -
Montana man settles lawsuit against J&J over increased amputation risk with Invokana drug, other cases remain pending
PHILADELPHIA – A lawsuit from a Montana man which claimed taking Johnson & Johnson’s Invokana medication for Type 2 diabetes caused him to be at increased risk for the gangrene he later developed has settled – while other cases from out-of-state plaintiffs remain pending in Philadelphia courts. -
Judge in landmark $8 billion Risperdal case cuts punitive damages award down to $6.8 million
PHILADELPHIA – After a Philadelphia jury rendered a staggering $8 billion punitive damages verdict at the end of a recent trial surrounding anti-psychotic drug Risperdal in October, the judge who presided over the trial reduced the verdict to $6.8 million on Friday. -
After $8 billion verdict, J&J wins two Risperdal cases in Philadelphia
PHILADELPHIA – In stark contrast to the $8 billion punitive damages verdict reached this past fall, two Risperdal cases were dismissed through successful motions for summary judgment from Johnson & Johnson in Philadelphia courtrooms. -
Philadelphia now the top-ranked 'Judicial Hellhole'; Massive verdicts, like $8B Risperdal case, cited
WASHINGTON – In an annual report of “Judicial Hellholes” released today by the American Tort Reform Association, Philadelphia has claimed the No. 1 ranking – in part due to a historic $8 billion punitive damages verdict rendered this year in litigation connected to Johnson & Johnson’s anti-psychotic drug Risperdal. -
Settlement talks in J&J exec's tragic flight lawsuit against Southwest Airlines extended for sixth time
PHILADELPHIA – Settlement proceedings have been granted a sixth time extension to obtain further evidence, in an action filed by a man on board the infamous Southwest Airlines flight from April 2018 where one passenger was partially sucked out of the plane and later died. -
More bad news from Pa. court for J&J as it fights Risperdal lawsuits
PHILADELPHIA – The Superior Court of Pennsylvania has both upheld a $70 million compensatory damages award given to a Tennessee plaintiff in a case tied to the anti-psychotic drug Risperdal, and set the stage for another fight on punitive damages against Johnson & Johnson – which recently yielded a historic $8 billion verdict in a Philadelphia courtroom, in another action. -
Pa. Supreme Court reinstates thousands of Risperdal cases after J&J argued they were filed too late
HARRISBURG – According to a pair of majority rulings from the Supreme Court of Pennsylvania, a factual analysis must be undertaken in each individual case involving Johnson & Johnson anti-psychotic drug Risperdal, before a jury can decide when the statute of limitations begins to toll for bringing a claim. -
Somewhere, Tim Robbins is laughing at Philadelphia
"That’s like saying, ‘I want gajillion bajillion dollars!’” -
Plaintiffs lawyers welcome judges from litigation hotbeds to conference in Las Vegas
LAS VEGAS (Legal Newsline) – Two judges involved in two of the most high-profile series of legal actions in the country were panelists at a Las Vegas conference organized by plaintiff lawyers. -
Judge accused of high-fiving jurors after $8B Risperdal verdict refuses to step down from trial
PHILADELPHIA – A Philadelphia judge has struck down an attempt to recuse him from future proceedings surrounding a staggering $8 billion punitive damages verdict at the end of a recent trial surrounding anti-psychotic drug Risperdal. -
Judge in $8 billion Risperdal trial high-fived the jury, Johnson & Johnson says
PHILADELPHIA – Johnson & Johnson, which was recently hit with a staggering $8 billion punitive damages verdict at the end of a recent trial surrounding anti-psychotic drug Risperdal in Philadelphia, has filed motions to set it aside and call for a retrial – in addition to calling for the presiding judge to recuse himself from the case moving forward, alleging improper conduct like high-fives and pictures with jurors. -
Two new mass torts for Philadelphia: Vena Cava Filters and Essure
PHILADELPHIA – As the year begins to draw to a close, filings in the Philadelphia County Court of Common Pleas’s Complex Litigation Center have increased with the presence of two new mass tort programs for Vena Cava Filters and the Essure birth control device, both of which feature a number of out-of-state plaintiffs and counsel. -
Attorney: $8 billion Risperdal verdict is 'another black eye' to Philadelphia's reputation
PHILADELPHIA – Johnson & Johnson and its subsidiary Janssen Pharmaceuticals have called a Philadelphia jury’s gigantic verdict of $8 billion in punitive damages against it for alleged malice connected to the marketing of anti-psychotic drug Risperdal “grossly disproportionate” and “a violation of due process” and are seeking to immediately overturn it. -
Breaking: In first test, Philadelphia jury punishes J&J with $8 billion verdict; Thousands more cases remain
PHILADELPHIA – In an unprecedented conclusion to the first-ever punitive damages trial tied to Risperdal, a 12-person jury found Johnson & Johnson and its subsidiary Janssen Pharmaceuticals liable for allegedly knowing and consciously disregarding the potential of the drug to cause gynecomastia to patients like plaintiff Nicholas Murray, and rendered a staggering verdict of $8 billion. -
Despite emails between J&J doctor and statistician, doctor says she played no role in Risperdal reanalysis
PHILADELPHIA – Cross-examination of a Johnson & Johnson doctor in the Risperdal punitive damages trial continued on Tuesday, with the physician stating that despite a number of email messages between herself and a statistician, that she played no role in the reanalysis of the drug’s data in 2015. -
Plaintiff counsel: Independent biostatistician tapped to review Risperdal data was actually J&J consultant
PHILADELPHIA – A plaintiff attorney in the punitive damages trial for Risperdal argued Friday that an independent biostatistician who reviewed the drug’s data for a reanalysis conducted in 2015, was in fact a former consultant for Johnson & Johnson who had worked on other litigation the company was involved in.